Vutrisir­an CAS 1867157-35-4

• Iden­ti­fi­ca­tion
• Prop­er­ties
• Safe­ty Data
• Spec­i­fi­ca­tions & Oth­er Information
• Links
• Quick Inquiry

Iden­ti­fi­ca­tion

CAS Number

1867157-35-4

Name

Vutrisir­an

Prop­er­ties

Safe­ty Data

Sym­bol

Sig­nal Word

Warn­ing

WGK Germany

3

MSDS Download

Spec­i­fi­ca­tions and Oth­er Infor­ma­tion of Our 

Iden­ti­fi­ca­tion Methods

HNMR, HPLC

Puri­ty

Known Appli­ca­tion

Vutrisir­an is an inves­ti­ga­tion­al sub­cu­ta­neous­ly admin­is­tered RNAi ther­a­peu­tic indi­cat­ed for the treat­ment of transthyretin-medi­at­ed (ATTR) amy­loi­do­sis, includ­ing hAT­TR and wild-type ATTR (wtAT­TR) amy­loi­do­sis. It blocks the pro­duc­tion of wild-type and vari­ant transthyretin (TTR) by tar­get­ing and silenc­ing spe­cif­ic mRNAs.

Gen­er­al View of Documents

Links

This prod­uct is devel­oped by our R&D com­pa­ny Wat­son Bio Lim­it­ed (https://​www​.wat​son​-bio​.com/).

Quick Inquiry

Fill out our inquiry form and one of our experts will be in touch with you shortly.